Taiwan's New Functional Food Regulations 2026: What Brands and Buyers Need to Know

Taiwan's health supplement regulatory framework is going through its most significant restructuring in a decade. Three concurrent regulatory moves in 2026 are reshaping the rules for functional ingredients, Chinese herbal materials in food, and product naming. For Taiwanese manufacturers and for Southeast Asian buyers sourcing from Taiwanese suppliers, understanding these changes before they take full effect is a real competitive advantage — and for brands that move last, a compliance catch-up cost.

The Structural Gap This Reform Is Closing

Taiwan's current regulatory structure creates a binary divide that strands most manufacturers.

On one end: the formal Health Food permit (健字號), which allows substantiated health function claims. The approval process typically runs one to three years depending on the pathway used (animal trial method or literature review), making it impractical for most mid-size manufacturers. On the other end: general food products, which cannot make any health function claims regardless of the science behind their ingredients.

Most manufacturers with evidence-based formulas fall in the middle and cannot communicate their product's value effectively. The 2026 regulatory moves are designed to address this gap — and they create a window for early-movers to establish compliance positioning before competitors respond.

Three Key Regulatory Developments in 2026

February 4, 2026 — Health Food Hygiene Standards Updated

The Ministry of Health and Welfare revoked the 1988 Health Food Hygiene Standards and a new version took effect. This update raises benchmarks across ingredient purity, heavy metal limits, and microbiological specifications for all products holding or applying for the Health Food (健字號) certification. Higher compliance bar, but also a clearer quality signal: manufacturers can credibly communicate "produced to Taiwan's 2026 health food hygiene standards" as a consumer trust marker.

April 13, 2026 — Draft Regulation on Herbal Materials in Food (Draft Stage — Not Yet in Force)

The MOHW Department of Chinese Medicine and Pharmacy announced a 60-day public comment period for the draft "Criteria for Chinese Medicinal Materials Permitted as Food Ingredients." This draft proposes two categories:

Category 1 (75 items): Herbs with established food consumption culture and confirmed safety — including lily bulb, lotus leaf, Chinese yam, tremella mushroom, jujube, and goji berry. These may be used freely as food ingredients.

Category 2 (73 items): Herbs requiring safety considerations, including Chinese angelica root (dong quai), astragalus, and adzuki bean. These carry maximum daily intake limits. If a Category 2 herb accounts for more than 50% of the product's main ingredients, the product may be subject to pharmaceutical classification review.

The same draft prohibits health supplement products from using names identical to 38 traditional Chinese medicine formulas recorded in classical texts — including Four Substance Decoction (四物湯), All-Inclusive Great Tonifying Decoction (十全大補湯), and Tortoise-Deer Two Immortals Glue (龜鹿二仙膠). This remains a draft and has not yet taken legal effect.

May 27, 2026 — Policy Consultation on Functional Food Grading (Under Development — No Confirmed Date)

TFDA held a stakeholder policy consultation meeting on adding a new "functional food" tier between general foods and the certified Health Food (健字號) category. The proposed direction: approximately 17 specified ingredients — including glucosamine, lutein, probiotics, fish oil, GABA, ginseng, collagen, and others — would require product registration on a designated platform, with permitted claims drawn from an approved positive list only.

This framework remains in the research and stakeholder communication phase. There is no confirmed implementation date or final regulatory text. All details subject to official TFDA announcement.

What This Means Practically

Product naming: review now

If any of your product names or marketing copy reference classical formula terms like "Four Substances," "Great Tonic," or "Tortoise-Deer," a compliance review is needed before the draft becomes law. Product renaming affects packaging, digital content, and distributor materials — starting the review now is substantially cheaper than reacting after the regulation passes.

Formulation review: know your ingredient category

For multi-herb formulas, understanding whether key ingredients fall into Category 1 or 2 — and whether the composition crosses the 50% threshold — is a supply chain risk assessment that belongs in your next OEM review meeting.

Functional claims: first-mover advantage

When the grading framework takes effect, approved positive-list claims give brands a legitimate, defensible way to communicate health benefits — a position not currently available in the general food category. Brands that prepare documentation and complete registration early establish a compliance-backed differentiator. Brands that wait will face both a compliance requirement and a competitive gap.

Why SEA Buyers Should Pay Attention

Taiwan's regulatory shift directly affects sourcing decisions across Southeast Asia. Buyers importing Taiwanese health supplements into Malaysia, Thailand, Vietnam, or the Philippines already manage multiple compliance layers. A Taiwanese supplier that can demonstrate TFDA-aligned documentation, clear ingredient categorization, and a compliance-ready formulation reduces the buyer's regulatory risk at the border.

Compliance capacity is becoming a supplier selection criterion — one that is harder to replicate than price alone.

Three Actions to Take Now

Audit product names against the 38 prohibited formula names in the draft regulation.

Map herbal ingredients to Category 1 or Category 2 and check usage levels against the draft daily limits.

Track TFDA functional food grading announcements — or contact MGHBIO for a regulatory update summary tailored to your product portfolio.

Contact MGHBIO for a compliant ingredient assessment mapped to your current product line: www.mghbio.com

⚠ Regulatory Disclaimer: All regulatory information in this article is based on official announcements from relevant government authorities. Items described as draft proposals have not yet entered into force; their final content and effective dates are subject to official publication. All claim examples are for reference only. Actual claims must be reviewed and confirmed by qualified regulatory consultants in each relevant jurisdiction.